{"entity":{"id":"fid-022","kind":"drug","name":"FID-022","aka":[],"tldr":"FID-022 is an experimental nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy from Fulgent Genetics, in phase 1 trials for advanced solid tumours.","summary":"FID-022 is a nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy (polyethyloxazoline material) from Fulgent Genetics. SN38 and its prodrug irinotecan encapsulated in a polyethyloxazoline (PEOX) material. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06694480 recruiting; dose levels 1-4 completed (July 2026 deck). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Fulgent Genetics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06694480"},{"label":"Fulgent Genetics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm"},{"label":"ClinicalTrials.gov: trials of FID-022","url":"https://clinicaltrials.gov/search?intr=FID-022"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["fulgent-genetics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06694480"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"FID-022","modality":"Nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy (polyethyloxazoline material)","mechanism":"SN38 and its prodrug irinotecan encapsulated in a polyethyloxazoline (PEOX) material.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fid-022/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"fulgent-genetics","kind":"company","name":"Fulgent Genetics","route":"/companies/fulgent-genetics/"}],"trial":[{"id":"nct06694480","kind":"trial","name":"Study of FID-022 in Participants With Advanced Solid Tumors","route":"/trials/nct06694480/"}]}}